Business Context and Reporting Period
This Form 8-K was filed by LIFECORE BIOMEDICAL, INC. on February 27, 2023. The report discloses a specific corporate governance event regarding executive compensation effective February 13, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change disclosed is an increase in the annual base salary for Jim Hall, the Company's Chief Executive Officer. The Compensation Committee approved raising his salary from $374,920 to $500,000.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific compensation adjustment.
Investor Verification Points
- Verify the effective date of the CEO salary increase (February 13, 2023).
- Confirm the new annual base salary amount ($500,000) versus the prior amount ($374,920).
- Review the Company's most recent 10-K or 10-Q for comprehensive financial performance data not included in this 8-K.